RF Safe argues that an FDA-authorized therapeutic radiofrequency device (TheraBionic P1) demonstrates biologically meaningful “non-thermal” RF effects, and contrasts this with consumer wireless regulation that it says is based primarily on heating (SAR) limits set in 1996. The post frames this as a regulatory and legal gap, citing the Radiation Control for Health and Safety Act and Telecommunications Act Section 704 as factors limiting local and public-health oversight. It also references several epidemiology and animal studies (e.g., Interphone, Hardell, CERENAT, IARC 2011 classification, and the U.S. NTP rodent studies) to support the claim that non-thermal effects and health risks warrant stronger scrutiny, though the article’s presentation is advocacy-oriented.